Bevatas 100mg (Bevacizumab)
Description of Bevatas 100mg (Bevacizumab 100mg)
Category: Monoclonal antibody or Anti-angiogenesis drug Bevacizumab is sold under the brand name Bevatas 100mg (Bevacizumab 100mg) which belongs to vascular endothelial growth factor directed antibody, the main ingredient which is used as Bevacizumab. Bevatas 100mg (Bevacizumab 100mg) consist of human framework regions and murine complementarity-determining regions. Bevatas 100mg (Bevacizumab 100mg) is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF)
INDICATIONS of Bevatas 100mg (Bevacizumab 100mg)
Bevatas 100mg (Bevacizumab 100mg)is indicated for the treatment :
• In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice for Metastatic colon or rectal cancer
• Concurrent use with carboplatin and paclitaxel as first line therapy for Non-squamous, non-small cell lung cancer
• Used in the treatment of recurrent Glioblastoma in adults
• Concurrent use with interferon alfa for Metastatic renal cell cancer
• Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan for Metastatic cervical cancer
• In combination with paclitaxel, pegylated liposomal doxorubicin or topotecan for Epithelial ovarian, fallopian tube or peritoneal cancer.
MECHANISM OF ACTION of Bevatas 100mg (Bevacizumab 100mg)
Bevatas 100mg (Bevacizumab 100mg)constitute an active ingredient like Bevacizumab which joined to VEGF and will not have communication of VEGF to its receptors like Flt-1 & KDR that present on the surface of the cells. While this interaction inhibits endothelial cell proliferation and new blood vessel production occurs Hence in counts discontinuation of metastatic tumor cells growth happens.
ADME of Bevatas 100mg (Bevacizumab 100mg)
The pharmacokinetic form of Bevatas 100mg (Bevacizumab 100mg) is assayed by measuring total serum Bevacizumab concentration.
Distribution:
The volume of distribution is 2.9 (22%) L
Elimination:
The terminal half life period of Bevacizumab is 20days (11 to 50days)
SIDE EFFECTS of Bevatas 100mg (Bevacizumab 100mg)
Gastrointestinal perforation and fistulae
Surgery and wound healing complication
Hemorrhage
Arterial thromboembolic events
Venous thromboembolic events
Hypertension
Posterior reversible encephalopathy syndrome
Renal injury & Proteinuria
Infusion reactions
Ovarian failure
Congestive heart failure
Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia.
PRECAUTIONS of Bevatas 100mg (Bevacizumab 100mg)
Caution with use in the conditions like;
Previously If you have taking or ever had DPD (dihydropyrimidine dehydrogenase) deficiency of enzyme . Inform the doctor about this then your doctor may preferably inform you avoid taking Bevatas 100mg (Bevacizumab 100mg). Discuss with the doctor that you have or have ever had renal, hepatic, or cardiac problem Discuss with the doctor that are you pregnant or plan to become pregnant. Avoid planning to have children while on treatment with Bevatas 100mg (Bevacizumab 100mg). You should use a essential method of conceiving to prevent pregnancy in yourself or your partner during your treatment with Bevatas 100mg (Bevacizumab 100mg). The drug will harm the fetus. Avoid breast feeding while on treatment with Bevatas 100mg (Bevacizumab 100mg)While using Bevatas 100mg (Bevacizumab 100mg)these are some other complications occurred during therapy, care should be taken Hypertension Posterior reversible encephalopathy syndrome Gastrointestinal perforations Wound healing complications Hemorrhage Arterial thromboembolic events Venous thromboembolic events Embryo fetal toxicity occurs
DRUG INTERACTION of Bevatas 100mg (Bevacizumab 100mg)
If you missed a dose take it as soon as possible, if time reach for next dose, While interaction of Bevatas 100mg (Bevacizumab 100mg) with paclitaxel & Carboplatin, leads to lowering in exposure of paclitaxel after four cycles of therapy. Interaction of Bevatas 100mg (Bevacizumab 100mg) with paclitaxel & Carboplatin leads to increase the paclitaxel exposure at day 6
PREGNANCY of Bevatas 100mg (Bevacizumab 100mg)
Pregnancy category: D while administrating Bevatas 100mg (Bevacizumab 100mg) in pregnant women, positive evidence on fetal risk depends on human studies but potential benefits by using the drug may have common risk against fetus.
LACTATION of Bevatas 100mg (Bevacizumab 100mg)
Bevatas 100mg (Bevacizumab 100mg)is excreted into breast milk taking account on this, discussion should done on whether to discontinue the breast feeding or the drug. While using the drug is unsafe during breast feeding to their infants
DOSAGE of Bevatas 100mg (Bevacizumab 100mg)
Key point :
Avoid administrating Bevatas 100mg (Bevacizumab 100mg) before at least 28 days following surgery and the wound is completely cured
Metastatic colorectal carcinoma :
The Bevatas 100mg (Bevacizumab 100mg)usual dosage by concomitant with 5-fluorouracil based chemotherapy. Bevatas 100mg (Bevacizumab 100mg)5mg/kg for every 2 weeks IV in concomitant with bolus IFL Bevatas 100mg (Bevacizumab 100mg)10mg/kg for every 2 weeks IV in combination with FOLFOX4 Bevatas 100mg (Bevacizumab 100mg)5mg/kg IV for every 2 weeks or Bevatas 100mg (Bevacizumab 100mg)7.5 mg/kg as IV every 3 weeks by concurrently take with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy
Non-small cell lung cancer :
The patients regular dosage of Bevatas 100mg (Bevacizumab 100mg)is 15mg/kg IV for every 3 weeks by interacting with carboplatin and paclitaxel
Glioblastoma :
Bevatas 100mg (Bevacizumab 100mg)10mg/kg administered IV for every 2 weeks
Metastatic renal cell cancer :
Concurrent use with interferon alfa.: The usual dose of Bevatas 100mg (Bevacizumab 100mg)is 10mg/kg IV for every 2 weeks
Metastatic cervical cancer :
The usual dose of Bevatas 100mg (Bevacizumab 100mg); Bevatas 100mg (Bevacizumab 100mg)15mg/kg given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan
Epithelial ovarian, fallopian tube or peritoneal cancer :
The usual dose of Bevatas 100mg (Bevacizumab 100mg)for Platinum opposing:; 10mg/kg of Bevatas 100mg (Bevacizumab 100mg)for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The regular dosage of Bevatas 100mg (Bevacizumab 100mg); 15mg/kg of Bevatas 100mg (Bevacizumab 100mg)given through IV for every 3 weeks by combining with topotecan The usual dose of Bevatas 100mg (Bevacizumab 100mg)for Platinum responsive; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Bevatas 100mg (Bevacizumab 100mg); 15mg/kg of Bevatas 100mg (Bevacizumab 100mg)given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles.
STORAGE of Bevatas 100mg (Bevacizumab 100mg)
Bevatas 100mg (Bevacizumab 100mg)vial should be stored at 2 to 8℃ (36 to 46℉) Single use vial Discard the left out medicine under guidance of pharmacist
MISSED DOSE of Bevatas 100mg (Bevacizumab 100mg)
If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose.
No reviews found